US FDA proposes stricter oversight of foreign tobacco makers

• Foreign manufacturers would need to provide detailed product information including nicotine concentration, flavors, package types, and for e-cigarettes, specifications like e-liquid volume and battery capacity
• Companies must register facilities annually and update product listings twice per year through the FDA's online system, matching requirements already imposed on U.S. manufacturers like Philip Morris International
• The rule would enable more effective FDA inspections of foreign facilities and provide better intelligence on tobacco products manufactured abroad for the U.S. market

Summary

The U.S. Food and Drug Administration (FDA) proposed new regulations on June 26 requiring foreign tobacco manufacturers to register their facilities and list products sold in the United States, aligning them with requirements already imposed on domestic producers.

Key Details:

The rule aims to close an existing regulatory loophole and enhance the FDA's ability to combat illegal imports, particularly youth-oriented e-cigarettes. While U.S. manufacturers like Philip Morris International already face federal registration and product listing requirements, foreign manufacturers currently have no such obligations.

Companies Affected:

Major global tobacco companies expected to be impacted include British American Tobacco, Japan Tobacco, and Imperial Brands, along with smaller overseas e-cigarette manufacturers exporting to the U.S. market.

Regulatory Requirements:

If implemented, foreign manufacturers must provide detailed product information including:

• Nicotine concentration and source
• Flavors, package types, and product dimensions
• For e-cigarettes: e-liquid volume, battery capacity, and wattage

Companies would need to submit information electronically through the FDA's online system, update facility registrations annually, and refresh product listings twice yearly.

Market Implications:

The proposal represents a significant regulatory tightening that could create compliance burdens for foreign tobacco companies and potentially restrict market access for non-compliant products. According to Bret Koplow, acting director of the FDA's Center for Tobacco Products, the goal is ensuring "all companies selling tobacco products in the United States should play by the same rules."

The rule would provide the FDA with enhanced oversight capabilities, including better information about foreign-made products and improved inspection effectiveness.